Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis
Titel:
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis
Auteur:
Kang, Yoon-Koo Qin, Shukui Lee, Keun-Wook Oh, Sang Cheul Kim, In-Ho Kim, Jong Gwang Li, Yong Yan, Zhuchen Li, Jin Bai, Li-Yuan Chan, Catherine Yusuf, Akeem Zahlten-Kümeli, Anita Taylor, Kate Yamaguchi, Kensei